Screener
Eligibility screening
Assess GTAEXS617 in Participants With Advanced Solid Tumors
Sponsored by Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.Study detailsClinicalTrials.gov
3 US sites in MI, TX, UT
Before we begin
Who are you filling this out for?
Your answer affects how the questions are phrased.